REPL · GS 13G/A: 3.3% stake

Goldman Sachs filed an amendment to its Schedule 13G for Replimune Group, disclosing beneficial ownership of 3,115,243 shares (3.3% of common stock) as of September 30, 2026. The filing is a routine passive stake update with no change in investment intent; the stake remains below 5% and consistent with prior filings.

• Goldman Sachs reports beneficial ownership of 3,115,243 shares of Replimune common stock
• Stake represents 3.3% of shares outstanding as of September 30, 2026
• Filing is an amendment to Schedule 13G, indicating passive investment intent
• Goldman Sachs certifies shares were acquired and held in ordinary course of business, not to influence control